Last update 21 Nov 2024

Alprazolam

Last update 21 Nov 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryAlprazolam is an agonist at the GABAA receptor, a key player in the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) pathway. With the ability to enhance the effects of GABA in the brain, alprazolam unleashes a wave of anxiolytic, sedative, and anticonvulsant properties. Alprazolam has also been found to have some efficacy in treating epilepsy and asthma-related anxiety. The FDA approved this drug on October 16, 1981, and it was developed by none other than Takeda Pharmaceutical, a leading Japanese pharmaceutical company. Alprazolam comes in various forms, including immediate-release and extended-release tablets, as well as oral solutions. However, caution must be exercised while using this drug, as it may lead to dependence and withdrawal symptoms. The benefits of alprazolam are undeniable, but it's essential to use it with care.

Drug Type

Small molecule drug

Synonyms

8-Chloro-1-methyl-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine, Alprazolcem

+ [17]

Target

DOCK5 x GABAA receptor

Mechanism

DOCK5 inhibitors(dedicator of cytokinesis 5 inhibitors), GABAA receptor agonists(Gamma-aminobutyric acid A receptor agonists)

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication

CatatoniaDepressive DisorderSleep Initiation and Maintenance Disorders+ [4]

Inactive Indication

Drug abuseMild asthmaPanic

Originator Organization

Takeda Pharmaceutical Co., Ltd.Upjohn Pharmaceuticals Ltd.

Active Organization

UCB Biopharma SRL

UCB Trading (Shanghai) Co., Ltd.

Teva Takeda Pharma Ltd.Startup

+ [5]

Inactive Organization

Viatris, Inc.

Engage Therapeutics, Inc.Startup

UCB, Inc.

+ [3]

Drug Highest PhaseApproved

First Approval Date

US (16 Oct 1981),

Anxiety DisordersPanic Disorder

RegulationBreakthrough Therapy (CN)

Structure

Molecular FormulaC17H13ClN4

InChIKeyVREFGVBLTWBCJP-UHFFFAOYSA-N

CAS Registry28981-97-7

110

Clinical Trials associated with Alprazolam

IRCT20240506061669N1 / RecruitingPhase 3IIT

Comparing the effect of Alprazolam (single dose) and Clonidine on improving the patient's stability under General Anesthesia

Start Date21 May 2024

Sponsor / Collaborator

Islamic Azad University

CTR20241558 / CompletedNot Applicable

阿普唑仑片在空腹及餐后条件下的人体生物等效性试验

[Translation] Bioequivalence study of alprazolam tablets in fasting and fed subjects

本研究考察健康受试者在空腹及餐后条件下，单次口服由湖南洞庭药业股份有限公司生产的阿普唑仑片（受试制剂，规格：0.4 mg）或由ヴィアトリス製薬株式会社（Viatoris制药株式会社）持证的阿普唑仑片（参比制剂，商品名：Solanax®，规格：0.4 mg）的药动学特征，评价两制剂的生物等效性及安全性，该受试制剂一致性评价提供依据。

[Translation]

This study examined the oral administration of a single dose of alprazolam tablets (test preparation, specification: 0.4 mg) produced by Hunan Dongting Pharmaceutical Co., Ltd. or Alprazolam tablets produced by Biotech Co., Ltd. to healthy subjects under fasting and postprandial conditions. (Viatoris Pharmaceutical Co., Ltd.) Pharmacokinetic characteristics of certified alprazolam tablets (reference preparation, trade name: Solanax®, strength: 0.4 mg), to evaluate the bioequivalence and safety of the two preparations, which subject Provide a basis for consistency evaluation of trial preparations.

Start Date14 May 2024

Sponsor / Collaborator

Hunan Dongting Pharmaceutical Co., Ltd.

NCT06293638 / RecruitingNot ApplicableIIT

Functional Brain Network Changes in Patients Undergoing Deep Brain Stimulation for Essential Tremor

The purpose of this study is to collect electrophysiological data related to functional brain network changes in patients undergoing deep brain stimulation for the treatment of essential tremor. Participants will be asked to remain seated with their head inside of a Magnetoencephalography (MEG) recording system as resting-state and task-related data are acquired. Spontaneous electrophysiological activity will be recorded in both the eyes open and eyes closed conditions with the participant seated comfortably. These recordings will be repeated in the DBS OFF and DBS ON states, with the ON state involving specific settings identified as optimal, sub-optimal, or ineffective at achieving tremor control. They will also be repeated following the optional administration non-DBS tremor mitigation techniques, which may include one or more of 1) cooling the limb, 2) oral administration of alprazolam, 3) oral consumption of ethanol (alcohol), or 4) peripheral nerve stimulation.

Start Date25 Mar 2024

Sponsor / Collaborator-

100 Clinical Results associated with Alprazolam

100 Translational Medicine associated with Alprazolam

100 Patents (Medical) associated with Alprazolam

2,686

Literatures (Medical) associated with Alprazolam

01 Jan 2025·Progress in Neuro-Psychopharmacology and Biological Psychiatry

Mother's little helper turned a foe: Alprazolam use, misuse, and abuse

Review

Author: Meisser, Noelle ; Vardeleon, Nathan I ; Steiner, Heinz ; Cardona-Acosta, Astrid M ; Bolaños-Guzmán, Carlos A

Benzodiazepines are effective in managing anxiety and related disorders when used properly (short-term). Their inappropriate use, however, carries significant risks, involving amnesia, rebound insomnia, rebound anxiety, depression, dependence, abuse, addiction, and an intense and exceedingly prolonged withdrawal, among other complications. Benzodiazepines also amplify the effects of opioids and, consequently, have been implicated in approximately 30 % of opioid overdose deaths. Despite their unfavorable profile, sharp increases in medical and non-medical use of benzodiazepines have been steadily reported worldwide. Alprazolam (Xanax®), a potent, short-acting benzodiazepine, is among the most prescribed and abused anxiolytics in the United States. This medication is commonly co-abused with opioids, increasing the likelihood for oversedation, overdose, and death. Notwithstanding these risks, it is surprising that research investigating how benzodiazepines, such as alprazolam, interact with opioids is severely lacking in clinical and preclinical settings. This review therefore aims to present our current knowledge of benzodiazepine use and misuse, with an emphasis on alprazolam when data is available, and particularly in populations at higher risk for developing substance use disorders. Additionally, the potential mechanism(s) surrounding tolerance, dependence and abuse liability are discussed. Despite their popularity, our understanding of how benzodiazepines and opioids interact is less than adequate. Therefore, it is now more important than ever to understand the short- and long-term consequences of benzodiazepine/alprazolam use.

01 Dec 2024·Sleep Medicine: X

Case report on melatonin overdose: Cause and concern

Article

Author: Bano, Hina ; Tripathi, Richa ; Alam, Mohd Rashid

Melatonin, the primary hormone secreted by the pineal gland, regulates central and peripheral oscillators and adapts the internal environment to the external one through MT1 and MT2 receptors. The authors present a case of 16-year-old male intentionally overdosed on 900mg of melatonin (180 tablets) and 10 tablets of 0.5mg alprazolam. Admitted to the emergency department, he was extremely drowsy and minimally responsive with a Glasgow coma scale score of 8/15. Vital signs were stable, and no renal or liver dysfunction was noted. Elevated total leucocyte count and positive benzodiazepine urine test were observed. Gastric lavage was performed, and toxicology reports showed blood alprazolam levels at 0.15 mg/litre eight hours post-overdose. The patient regained consciousness 32 hours post-ingestion and was transferred to the psychiatry unit. This case underscores the increasing abuse of melatonin due to its easy availability and lack of regulation. Although melatonin has a low toxicity potential, side effects and interactions with other drugs can be severe. Supportive measures and vital sign control are crucial in overdose treatment.

01 Dec 2024·Journal of Psychopharmacology

Evaluation of the sedative-motor effects of novel GABAkine imidazodiazepines using quantitative observation techniques in rhesus monkeys

Article

Author: Berro, Laís F ; Mian, Md Yeunus ; Sharmin, Dishary ; Rüedi-Bettschen, Daniela ; Platt, Donna M ; Pareek, Tanya ; Golani, Lalit ; Rashid, Farjana ; Reeves-Darby, Jaren A ; Cook, Jemma E ; Rowlett, James K ; Cook, James M ; Moreira-Junior, Eliseu da Cruz

Background: Benzodiazepines bind to γ-aminobutyric acid type A (GABAA) receptor subtypes identified by different α subunits (i.e., α1GABAA, α2GABAA, α3GABAA, and α5GABAA). Sedative-motor effects of benzodiazepines are thought to involve α1GABAA and α3GABAA subtypes. Aims: We evaluated observable measures of sedative-motor effects and species-typical behaviors in monkeys following acute administration of novel GABAkines (positive allosteric modulators of GABAA receptors), with varying degrees of selective efficacy at different GABAA receptor subtypes. We predicted that the induction of sedative-motor effects would depend on the degree of α1GABAA and α3GABAA efficacy. Methods: Adult female rhesus monkeys ( N = 4) were implanted with chronic indwelling i.v. catheters. Quantitative behavioral observation was conducted by trained observers following administration of multiple doses of the conventional benzodiazepine alprazolam and the GABAkines MP-III-80 (preferential efficacy at α2/α3/α5GABAA subtypes), KRM-II-81, MP-III-24 (both with preferential efficacy for α2/α3GABAA subtypes), and MP-III-22 (preferential potency and efficacy for α5GABAA subtypes). Results: As with alprazolam, all GABAkines induced significant levels of mild sedation (“rest/sleep posture”). Deep sedation was observed with alprazolam, MP-III-80, and MP-III-22; motoric effects (observable ataxia) were obtained with alprazolam, KRM-II-81, and MP-III-22 only. Surprisingly, the order of potency for rest/sleep posture was significantly associated only with potency at α5GABAA subtypes. Conclusions: GABAkines with preferential efficacy at α2/α3GABAA and/or α5GABAA subtypes engendered sedative-motor effects in monkeys, although only compounds with α5GABAA activity engendered deep sedation. Moreover, the significant relationship between potency obtained with in vitro electrophysiology data and the rest/sleep posture measure suggests a role for the α5GABAA subtype in this milder form of sedation.

News (Medical) associated with Alprazolam

18 Oct 2024

·www.prnewswire.com

Introducing Clear Behavioral Health's 15th Location for Addiction Recovery and Mental Health Treatment

Gardena's Premier Destination for Residential, In-Network Treatment GARDENA, Calif., Oct. 17, 2024 /PRNewswire/ -- The vibrant city of Gardena has welcomed an exciting addition to its wellness community with the grand opening of Clear Behavioral Health Residential Rehab Treatment Center. As Clear's 15th location within Los Angeles County, this comprehensive behavioral health facility will serve Gardena, the South Bay, and surrounding areas by providing a residential rehab and detox facility for addiction recovery and dual diagnosis treatment. Continue Reading Step inside Clear Behavioral Health's Residential Rehab Treatment Center in Gardena, CA. Serving Los Angeles County and surrounding areas by providing a residential rehab and detox facility for addiction recovery and dual diagnosis treatment. At this new 20 bed facility, clinicians treat a wide variety of substance use disorders and mental health conditions, including Alcohol/Opiate/Stimulant Use Disorder, Benzodiazepine dependence, dual diagnosis addiction w/ depression, anxiety, trauma, ADHD Staggering statistics forecast that only 28% of eligible Detox/Rehab/RTC individuals, and a mere 11% of eligible PHP/IOP individuals, will receive treatment in 2026. Clear's new facility aims to bridge that gap for those in need of care. The new location expands Clear's treatment capacity by 20 beds, enabling more individuals to receive comprehensive, evidence-based treatment that most major insurance providers cover. At this new Gardena facility, clinicians treat a wide variety of substance use disorders and mental health conditions, including Alcohol Use Disorder, Opiate Use Disorder (heroin, fentanyl, kratom, pain killers), Stimulant Use Disorder (methamphetamine, Adderall, crack/cocaine), Benzodiazepine dependence (Xanax, Klonopin), dual diagnosis disorders including addiction with depression, anxiety, trauma, ADHD, and other mental health diagnoses. Our highly individualized treatment plans are tailored to meet each client's needs at every step of their recovery journey. Dr. Martha B. Koo, MD, Chief Medical Officer and Clinical Supervisor of Clear Behavioral Health, brings unparalleled expertise and passion to addressing mental health solutions through Clear's services. Dr. Koo obtained her psychiatry residency training at the Resnick Neuropsychiatric Institute at UCLA and her subsequent psychoanalytic training at the New Center for Psychoanalysis. She is double Board-Certified in Psychiatry and Addiction Medicine and has over twenty years of psychiatric experience. "Our services at Clear Behavioral Health are designed to be highly individualized, evidence-based, and holistic, ensuring that each client receives care tailored to their unique needs," said Dr. Martha Koo. "We believe in treating the whole person—addressing not just the symptoms of mental health and addiction disorders but also the underlying issues. Our compassionate and experienced staff create a warm, welcoming environment that fosters healing and recovery, empowering individuals to reclaim their lives." Joining Dr. Koo's team as the Clinical Director of Clear's Substance Use Disorder Division is Jason Bernstein, LMFT. Jason holds a master's degree in clinical psychology from Antioch University. With over five years of experience in the substance use and mental health field, he is passionate about supporting individuals seeking dual diagnosis treatment on their journey toward healing, growth, and achieving emotional and psychological wellbeing. His commitment to providing compassionate care and fostering an environment conducive to recovery positions him as a valuable leader for the Gardena facility. "Our inpatient rehab provides the safety and comfort needed for individuals to detox and rehabilitate from addiction while also addressing underlying mental health disorders," said Jason Bernstein. "We are excited to welcome our first clients to Gardena, where we're proud to provide whole-person family-centered care. Every person deserves the opportunity to recover, grow, and live a functional, happy life." The Gardena facility features a home-like, safe, and clinical environment. Program Director Jamie Arthur, CATC, CADC-II, has over 10 years of experience in the substance use recovery field and is dedicated to ensuring clients receive a robust range of program services to launch their recovery. Services include: Round-the-Clock Clinical Staff: Our compassionate team led by Jason Giles, MD, and Brittany Skinner, PMHNP provides 24/7 supervised care. Peer Support: Group therapy sessions foster a sense of unity while providing the space to develop healthy relationships. Medication Management: Safe transitions into detox help patients regain mental and physical stability as comfortably as possible. Therapy and Counseling: Individual therapy and counseling help patients uncover the root of their mental health struggles and develop tools to regain self-trust and balance. Experiential Therapies: Group therapeutic wellness activities such as yoga, meditation and sound healing enhance recovery. In addition to the Gardena launch, Clear Behavioral Health has recently opened facilities in Van Nuys and El Segundo, providing outpatient mental health treatments for adults and teens. These locations offer Intensive Outpatient Programs (IOP), including individual therapy, peer support, holistic therapies, and academic counseling. Founded in 2015, Clear Behavioral Health is a subsidiary of Your Behavioral Health, a leading regional provider of mental health and addiction treatment services for adults and teens, with 28 facilities and growing throughout Southern California. Your Behavioral Health provides the full continuum of behavioral health care, including detox, outpatient (PHP/IOP), interventional psychiatry, and residential care across its family of brands — which includes Clear Behavioral Health, New Life House, and Neuro Wellness Spa — and delivers specialized programs for depression, anxiety, trauma-related issues, addiction and other mental health conditions. Co-founders Mike Joly, Chief Executive Officer, and Dr. Martha Koo, Chief Medical Officer, lead Your Behavioral Health alongside an expert team of clinicians across Southern California. For more information about Clear Behavioral Health or to schedule a free consultation, please visit our website at or call us at 877-564-5571. About Clear Behavioral Health ClClear Behavioral Health, formerly Clear Recovery Center, is a leading Los Angeles-based provider of comprehensive, in-network behavioral health treatment programs. Our mission is simple: to help those struggling with mental health and addiction live healthy and purposeful lives. Our unique story started with a vision to make clinically excellent, highly individualized mental health services accessible to all. For a list of our 15 locations, visit . About Your Behavioral Health Your Behavioral Health is a leading regional behavioral health services platform providing comprehensive, best-in-class services for adults and teens across the continuum of mental health and addiction treatment. With state-of-the-art facilities across Southern California, expert clinical teams, and a pioneering evidence-based approach, Your Behavioral Health offers specialized residential, inpatient, and outpatient programs for a range of mental health conditions. Its family of brands includes Clear Behavioral Health, New Life House, and Neuro Wellness Spa. For more information, please visit . Contact: Stephanie Paz Townsend (310) 295-0429 [email protected] SOURCE Clear Behavioral Health WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

11 Sep 2024

·medcitynews.com

300+ Provider Organizations Urge Feds to Prevent Leaked DEA Rule From Going into Effect - MedCity News

More than 330 healthcare organizations signed letters this week urging the White House and Congress to extend a telehealth prescribing flexibility that was introduced during the Covid-19 pandemic. Failure to extend this policy would cause millions of Americans to lose access to “critically important healthcare treatment,” the organizations wrote. In 2020, Congress waived a rule that required an in-person visit to establish a relationship between a patient and their provider before any prescriptions can be given via telehealth. The Drug Enforcement Administration had originally planned to roll back this flexibility last year, but the agency extended it through the end of 2024 after receiving more than 38,000 comments on its proposed rule. presented by Health Tech The Promise of Value-Based Care and MedTech Innovation Monica Vajani, Executive Director for mHUB’s MedTech Accelerator, discusses how mHUB is helping innovators transition healthcare towards value-based care. By Monica Vajani For nearly four years now, providers have been using the telehealth prescribing flexibility to prescribe controlled substances. These include Schedule II drugs, such as stimulant medications to treat ADHD like Adderall and Vyvanse, as well as opioids like Percocet and Dilaudid. These also include Schedule III-V controlled substances, such as common psychiatric drugs like Xanax, Ambien and Prozac, as well as drugs that treat substance use disorder like buprenorphine. The DEA is still working on a new proposed rule that will dictate whether or not providers can prescribe controlled substances via telehealth after this year — but last week, its plans were leaked by media outlets. The agency’s rule — which is not final and is currently being reviewed at the White House — is definitely not what telehealth advocates were calling for. The rule would get rid of providers’ ability to prescribe Schedule II drugs via telehealth without a prior in-person appointment — either by establishing new regulations or simply allowing the pandemic-era flexibility to expire at the end of the year. On the other hand, Schedule III-V drugs would still be allowed to be prescribed via telehealth without an in-person visit. Sponsored Post What Healthcare Can Learn from Costco The path forward is clear: employers must evaluate their health plan the same way they do their Saturday shopping excursion. By Jeff Bak, Imagine360 CEO and President Additionally, the unpublished rule would require that no more than half of a provider’s prescriptions may be given via telehealth appointment. It also includes a mandate for prescribers to check all 50 states’ prescription drug monitoring programs before writing a prescription for a patient with whom they have never had an in-person visit. However, enforcing this requirement will be difficult, as providers say there is no national registry where providers could easily check whether or not the patient had obtained a prescription for the drug in another state. Many provider organizations have reacted to the leaked rule with outrage. On Tuesday, more than 300 groups sent separate letters to the White House, Senate and House, imploring them to roll back the strict rules that the DEA is reportedly planning to propose. Some of these organizations included Amazon, Cleveland Clinic, Mass General Brigham, Hims & Hers Health, the American College of Physicians, and the National Rural Health Association. “The ongoing challenges in accessing mental health and substance use treatment services, particularly in rural and underserved areas, underscore the importance of maintaining these flexibilities. More than half of U.S. counties do not have a psychiatrist. The shortage is even more prominent in rural areas, with nearly three quarters of rural counties lacking a psychiatrist,” read the groups’ letter to the White House. Extending the prescribing flexibility would mean that millions of patients in these underserved areas would get to keep their access to treatment, the organizations argued in their letter. The letter also pointed out that there is very little time to make this happen. “Given how late we are in the year and with the waiver expiring on December 31, there is very little time left for the DEA to release a draft rule for public comment, close the comment period, review the substantive feedback, and finalize the rule in time for the end of the year. Nearly 40,000 comments were submitted last year when the DEA first attempted to draft rules for a permanent framework on remote prescribing of controlled substances,” it read.

26 Jul 2024

·www.drugs.com

Fake Oxycontin Pills Widespread and Potentially Deadly: Report

FRIDAY, July 26, 2024 -- The rate at which young Americans are ending up in hospital ICUs after using fake Oxycontin pills spiked with fentanyl is soaring, especially in the U.S. West, a new report warns. Medical toxicology data from one unnamed hospital in the western U.S. found the number of cases involving overdoses involving fake "M-30" Oxycontin pills rose from just three in 2017 to 209 during 2022, according to a team from the Centers for Disease Control and Prevention. Most patients (81%) required hospital care and more than two-thirds of those patients spent time in the ICU. Two patients died while hospitalized, the report found. Young men were the most likely victims: Males made up 71% of cases, and patients between the ages of 15 and 34 accounted for more than two-thirds of cases, said a team led by CDC researcher Emily Glidden . The hospital's experience reflects what's going on nationwide. "These findings are consistent with a broader trend that has been observed nationally and regionally," the team wrote in a report published July 25 in the CDC journal Morbidity and Mortality Weekly Report . They note that fake M-30 Oxycontin ( oxycodone ) pills first emerged on the illicit drug marketplace in the United States in 2014. They're typically laced with potentially deadly fentanyl and are either swallowed or crushed and inhaled, the researchers explained. They noted that by 2022, six in every 10 lots of counterfeit pills seized by law enforcement were found to contain potentially lethal levels of fentanyl. While many users may believe they are buying and consuming legitimate oxycodone pills, "evidence that some persons may purposefully use counterfeit pills with illegally made fentanyl exists," Glidden's group noted. There's data to suggest that people addicted to injected heroin might now be consuming fentanyl-laden counterfeit pills to achieve a needle-free high, the team explained. Too often, the consequences of doing so can be deadly. The CDC team point to other data showing that deaths linked to the use of counterfeit pills tripled in the U.S. West between July 2019 and December of 2021, although such cases are rising nationwide. More than half (57.1%) of those who died were under the age of 35. The danger to teens is especially troubling: Overdose deaths involving counterfeit pills containing fentanyl "sharply increased across 31 states" between mid-2019 and late 2021, the researchers noted, with counterfeit pills implicated in a quarter of all teen deaths caused by ODs. In the vast majority of overdose cases seen at the hospital that was the focus of Glidden's study, other illicit substances were also involved. Besides fentanyl, drugs such as meth (66.2% of cases), benzodiazepines such as Xanax or Valium (17%) or cocaine (5.1%) were also detected in patient's systems. What can and should be done to reduce deaths and hospitalizations? According to Glidden's team, "outreach focusing on younger persons misusing prescription pills, improving access to harm reduction [interventions], and linking patients treated for overdoses in hospitals to substance use treatment might help prevent overdoses involving counterfeit pills." Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical ResultClinical Study

100 Deals associated with Alprazolam

External Link

KEGG	Wiki	ATC	Drug Bank
D00225	Alprazolam	N05BA12	DB00404

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Catatonia	JP	Teva Takeda Pharma Ltd.Startup	15 Feb 1984
Depressive Disorder	JP	Teva Takeda Pharma Ltd.Startup	15 Feb 1984
Depressive Disorder	JP	VIATRIS Pharmaceuticals Ltd.	15 Feb 1984
Sleep Initiation and Maintenance Disorders	JP	Teva Takeda Pharma Ltd.Startup	15 Feb 1984
Sleep Initiation and Maintenance Disorders	JP	VIATRIS Pharmaceuticals Ltd.	15 Feb 1984
Anxiety Disorders	US	Upjohn US 2 LLC	16 Oct 1981
Panic Disorder	CN	-	-

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Status Epilepticus	Phase 3	US	UCB Biopharma SRL	07 Dec 2021
Status Epilepticus	Phase 3	AU	UCB Biopharma SRL	07 Dec 2021
Status Epilepticus	Phase 3	IT	UCB Biopharma SRL	07 Dec 2021
Status Epilepticus	Phase 3	CZ	UCB Biopharma SRL	07 Dec 2021
Status Epilepticus	Phase 3	FR	UCB Biopharma SRL	07 Dec 2021
Epilepsy	Phase 3	-	UCB SA	-
Anxiety Disorders	Phase 2	US	UCB, Inc.	19 Jan 2005
Panic Disorder	Phase 2	US	UCB, Inc.	19 Jan 2005

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04782388 (UP0101, AAN2024)	Phase 1	-	-	Staccato Alprazolam 2 mg	(ttmknbqmre) = AUC0-t showed a similar trend to AUCinf dwrgclfxfr (cocrnuqhra ) View more	Positive	09 Apr 2024
				Staccato Placebo
NCT04970342 (PDID, CTgov)	Phase 1	-	13	Placebo (Lactose) Capsule+Cannabis (0%/ THC / 0% CBD) ("Sober" or Double Placebo)	hscalxprfw(ilivfchhly) = ugktfbbmwn yufnwbakqp (wzwxhpixal, iryvaqpgmp - icgmifobqv) View more	-	25 Jul 2023
				Cannabis (0%/ THC / 0% CBD)+0.75 mg Alprazolam Capsule (Active Alprazolam (Xanax), Placebo Cannabis)	hscalxprfw(ilivfchhly) = qcwgybneei yufnwbakqp (wzwxhpixal, manslnelwi - trvrucnaaa) View more
NCT03478982 (ENGAGE-E-001, Pubmed)	Phase 2	Epilepsy	116	Staccato® alprazolam 1.0 mg	wagfqspwkn(jhkxrhqceu) = vmxcwusqcl lyoctbcgpf (mncjqssycb )	-	21 Oct 2022
				Staccato® alprazolam 2.0 mg	wagfqspwkn(jhkxrhqceu) = mccspgilrr lyoctbcgpf (mncjqssycb )
NCT03478982 (P1.5-023, AAN2019)	Phase 2	Epilepsy	8	Staccato Alprazolam 1 mg	(uujcvlefit) = no adverse events were serious or severe xnvbtzxgpl (wkvxjtlrls )	Positive	09 Apr 2019
NCT03447353 (CTgov)	Phase 4	-	18	Placebo Oral Tablet ("Sober" or Double Placebo)	cblxdxaoau(pmafdppibo) = wyfupeuwhq usiqhsipdc (kewcbjzmwy, whdlaoqqiv - fyselqfjfw) View more	-	27 Sep 2018
				Norco 10Mg-325Mg Tablet+Xanax 1Mg Tablet (Active Xanax, Active Norco)	cblxdxaoau(pmafdppibo) = wrxywthrwj usiqhsipdc (kewcbjzmwy, quatjrtjdq - rghsoopmzl) View more
NCT00477451 (CTgov)	Phase 2	Panic \| Panic Disorder	49	Inhaled placebo+IV doxapram (RCT Placebo)	rdkgbxkdsy(xtgghtlxic) = eukilccqic zewhqxpest (xgeomviqjd, vcahnynriz - agrtxhqqvq) View more	-	16 Jun 2017
				IV doxapram+Inhaled alprazolam 1 mg (RCT Alprazolam 1 mg)	rdkgbxkdsy(xtgghtlxic) = ycwtxixzfp zewhqxpest (xgeomviqjd, eqwoogsdek - legvgafnxh) View more
NCT01577706 (CEBRA2, CTgov)	Not Applicable	Substance Abuse	7	Placebo (Placebo)	xvwgiwivtc(kfbxnczfkl) = qosrmvbczx csyusnzzzg (fphukvthku, jyovesvqql - rrxcoykcqo) View more	-	04 Apr 2017
				Alprazolam (Alprazolam)	xvwgiwivtc(kfbxnczfkl) = chnubpzmcg csyusnzzzg (fphukvthku, oygdqljbmf - zcvoaghgfe) View more
NCT00603980 (Pubmed \| Psychopharmacology (Berl))	Phase 1	Drug abuse	14	Inhaled alprazolam	uenjwhtlus(mipvhkvdft) = brgovxmzwy xkwciifzwb (kwyeqvnmvy )	-	01 Mar 2015
				Oral alprazolam	uenjwhtlus(mipvhkvdft) = mwmflqvbkp xkwciifzwb (kwyeqvnmvy )
NCT00356278 (CTgov)	Phase 2/3	Stress Disorders, Post-Traumatic	156	D-cycloserine (VRE Therapy and D-cycloserine)	pibicdtfvp(bkxzjzjckb) = obnftvwusy dxksrkhorz (ikyqcwkqho, afpcecbyzc - raptgdcita) View more	-	19 Nov 2014
				Alprazolam (VRE Therapy and Alprazolam)	pibicdtfvp(bkxzjzjckb) = cxwgdqfoiu dxksrkhorz (ikyqcwkqho, dqddglwwhb - jkafttihbg) View more
NCT01949038 (Pubmed \| Endoscopy)	Phase 2/3	-	220	Sublingual alprazolam	xvbtpumsrt(ntcdujlwsn) = pkznmhdkln kneffdzkkk (lgxlmghtby )	Positive	01 Aug 2014
				Oral alprazolam	xvbtpumsrt(ntcdujlwsn) = sjijfzcntt kneffdzkkk (lgxlmghtby )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis